Obtustatin isa41aminoaciddisintegrinpeptideisolatedfromthevenomoftheViperalebetinaobtusa.Itisapotent(IC50 =2nM)and selectiveinhibitorofthebindingofα1β1 integrintocollagenIV.Contrarytootherknowndisintegrins,itdoesnotcontaintheclassicalRGDsequence. Obtustatin doesnotshowinhibitoryactivitytowardotherintegrins,includingα2β1,αIIbβ3,αvβ3,α4β1,α5β1,α6β1,andα9β1,α4β7 integrins. Obtustatin potentlyinhibitsangiogenesisinchickenandinmousemodelandreducestumordevelopmentbyhalf.
AAsequence: Cys1-Thr-Thr-Gly-Pro-Cys6-Cys7-Arg-Gln-Cys10-Lys-Leu-Lys-Pro-Ala-Gly-Thr-Thr-Cys19-Trp-Lys-Thr-Ser-Leu-Thr-Ser-His-Tyr-Cys29-Thr-Gly-Lys-Ser-Cys34-Asp-Cys36-Pro-Leu-Tyr-Pro-Gly-OH
Disulfidebonds: Cys1-Cys10,Cys6-Cys29,Cys7-Cys34 andCys19-Cys36
Length(aa): 41
Formula: C184H284N52O57S8
MolecularWeight: 4393.13 Da
Appearance:Whitelyophilizedsolid
Solubility: aqueousbuffer
CASnumber: notavailable
Source: Synthetic
Purityrate: >97%
ObtustatinandLebestatinarelysine-threonine-serine(KTS)-disintegrins,whichareafamilyoflowmolecularweightpolypeptidespresentinmanyviperidaevenomsandarepotentandspecificinhibitorsofcollagen-bindingintegrins.Theintegrinbindingloop,harboringthe(21)KTS(23)motif,andtheC-terminaltailareknowntoberesponsIBLefortheselectivebindingtotheα1β1integrin.Despiteaveryhighsequencehomology(onlytwomutationsarepresentinLebestatinrelativetoObtustatin,namelyR24LandS38L),LebestatinexhibitsahigherinhibitoryeffectthanObtustatinoncelladhesionandcellmigrationtocollagensIandIV.Hereweshow,bymeansofmoleculardynamicssimulationsofthetwopolypeptidesinaqueoussolution,thatLebestatinpossessesahigherflexibilityoftheC-terminaltailandagreatersolventaccessibilityoftheintegrinbindingloopthanObtustatin.Itmaybehypothesizedthatthesepropertiesmaycontributetothehigherbinding-affinityofLebestatintoitsBIOLOGicalpartner.©2012WileyPeriodicals,Inc.
DaidoneI, etal. (2013)StructuralanddynamicalpropertiesofKTS-disintegrins:AcomparisonbetweenObtustatinandLebestatin. Biopolymers. PMID: 23097229
Thepresentedresultsshowtheeffectoftargetingofcollagenreceptor,alpha1beta1integrinexpressedontheendothelialcellsonthedevelopmentofexperimentalmelanomaandpathologicalangiogenesis.Obtustatin,asnakevenomKTS-disintegrin,wasappliedasaspecificinhibitorofthisintegrin.Thislowmolecularweightpeptiderevealedapotenttherapeuticeffectonmelanomaprogressionin2animalsystems,mouseandquail.Itsoncostaticeffectwasrelatedtotheinhibitionofangiogenesis.ObtustatininhibitedtheneovascularizationratioontheCAMembryoofquail,whichwaspathologicallyinducedbythedevelopingtumor.Thei.v.admiNISTrationofobtustatincompletelyblockedcancergrowthofMV3humanmelanomainnudemice.InB16F10syngeneicmousemodeltreatmentwiththedisintegrinrevealedalowereffect,althoughthedevelopmentofthetumorwassignificantlyreducedforbothdosages.Themechanismofobtustatinactionisrelatedtotheblockingofmicrovascularendothelialcellproliferation,whichundergoesapoptosisincaspase-dependentmanner.Summarizing,wepresentstudiesoflowmolecularweightdisintegrin,obtustatinasapotentialtherapeuticcompoundfortreatmentofmelanomathatcontainahighlevelofvascularization.
BrownMC, etal. (2008)Angiostaticactivityofobtustatinasalpha1beta1integrininhibitorinexperimentalmelanomagrowth.IntJCancer. PMID: 18712720
Integrinsalpha(1)beta(1)andalpha(2)beta(1)arehighlyexpressedonthemicrovascularendothelialcells,andblockingoftheiradhesivepropertiessignificantlyreducedtheVEGF-drivenneovascularizationratioandtumorgrowthinanimalmodels.Hence,inhibitorsofthealpha(1)beta(1)andalpha(2)beta(1)integrins,aloneorincombinationwithantagonistsofotherintegrinsinvolvedinangiogenesis(eg.alpha(v)beta(3),alpha(v)beta(5),andalpha(6)beta(4)),mayprovebeneficialinthecontroloftumorneovascularization.Viperidaesnakeshavedevelopedintheirvenomsanefficientarsenalofintegrinreceptorantagonists.KTS-(obtustatin,viperistatin,lebestatin)andRTS-(jerdostatin)disintegrinsrepresentvipervenompeptidesthatspecificallyblocktheinteractionofthealpha(1)beta(1)integrinwithcollagensIVandIinvitroandangiogenesisinvivo.Thepossibletherapeuticapproachtowardstumorneovascularizationbytargetingthealpha(5)beta(1),alpha(v)beta(5)andalpha(v)beta(3)integrinswithRGD-bearingdisintegrinshasbeenexploredinanumberoflaboratories.Herewediscussstructure-functioncorrelationsofthenovelgroupofspecific(K/R)TS-disintegrinstargetingthealpha(1)beta(1)integrin.
CalveteJJ, etal. (2007)KTSandRTS-disintegrins:anti-angiogenicvipervenompeptidesspecificallytargetingthealpha1beta1integrin. CurrPharmDes. PMID: 17979730
Disintegrinsrepresentagroupofcysteine-richpeptidesoccurringinCrotalidaeandViperidaesnakevenoms,andarepotentantagonistsofseveralintegrinreceptors.Anoveldisintegrin,obtustatin,wasisolatedfromthevenomoftheViperalebetinaobtusaviper,andrepresentsthefirstpotentandselectiveinhibitorofthebindingofintegrinalpha(1)beta(1)tocollagenIV.Theprimarystructureofobtustatincontains41aminoacidsandistheshortestdisintegrindescribedtodate.Obtustatinsharesthepatternofcysteinesofothershortdisintegrins.However,incontrasttoknownshortdisintegrins,theintegrin-bindingloopofobtustatinistworesiduesshorteranddoesnotexpresstheclassicalRGDsequence.Usingsyntheticpeptides,aKTSmotifwasidentifiedastheintegrin-bindingsequence.Athree-dimensionalmodelofobtustatin,builtbyhomology-modelingstructurecalculationsusingdifferenttemplatesandalignments,stronglyindicatesthatthenovelKTSmotifmayresideatthetipofaflexibleloop.
Moreno-MurcianoM.P., etal.(2003)Aminoacidsequenceandhomologymodelingofobtustatin,anovelnon-RGD-containingshortdisintegrinisolatedfromthevenomofViperalebetinaobtusa. ProteinSci. PMID: 12538900
Anoveldisintegrin,obtustatin,waspurifiedfromthevenomoftheViperalebetinaobtusaviper.Obtustatinistheshortestdisintegrinyetdescribed,containingonly41aminoacids.ItcontainsasimilarpatternofcysteinestotheshortdisintegrinsechistatinanderistostatinbutcontainsthesequenceKTSratherthanRGDinitsactivesiteloop.Obtustatinisapotentandselectiveinhibitorofalpha1beta1integrin.Itdoesnotinhibitthecloselyrelatedintegrinalpha2beta1,norapanelofotherintegrinstested.Itdoesnotinhibitligandbindingtotherecombinantalpha1I-domain.Importantly,obtustatinpotentlyinhibitedangiogenesisinvivointhechickenchorioallantoicmembraneassay,andintheLewislungsyngeneicmousemodel,itreducedtumordevelopmentbyhalf,confirmingandextendingpreviousresultsontherelevanceofalpha1beta1integrintoangiogenesisandsuggestingnovelapproachestothegenerationofangiogenesisinhibitors.
MarcinkiewiczC., etal.(2003)Obtustatin:apotentselectiveinhibitorofalpha1beta1integrininvitroandangiogenesisinvivo. CancerRes. PMID: 12727812
Thesolutionstructureofobtustatin,anovelnon-RGDdisintegrinof41residuesisolatedfromViperalebetinaobtusavenom,andapotentandselectiveinhibitoroftheadhesionofintegrinalpha(1)beta(1)tocollagenIV,hasbeendeterminedbytwo-dimensionalnuclearmagneticresonance.Almostthewholesetofchemicalshiftsfor1H,13Cand15Nwereassignedatnaturalabundancefrom2Dhomonuclearandheteronuclear500MHz,600MHzand800MHzspectraatpH3.0recordedat298Kand303K.Finalstructuralconstraintsconsistedof302non-redundantNOE(95long-range,60medium,91sequentialand56intra-residue),fourdisulfidebonddistances,fivechi1dihedralanglesandfourhydrogenbonds.The20conformerswithlowesttotalenergyhadnoNOEviolationsgreaterthan0.35Aordihedralangleviolationsgreaterthan12degrees.Theaverageroot-mean-squaredeviation(RMSD)forbackboneatomsofallresiduesamongthe20conformerswas1.1Aand0.6Aforthe29best-definedresidues.Obtustatinlacksanysecondarystructure.ComparedtoallknowndisintegrinstructuresinwhichtheRGDmotifislocatedattheapexofan11residuehairpinloop,theactiveKTStripeptideofobtustatinisorientedtowardsasideofitsnineresidueintegrin-bindingloop.TheC-terminaltailisneartotheactiveloop,andthesetwostructuralelementsdisplaythelargestatomicdisplacementsduetolocalconformationaldisorder.Doublecross-peaksforW20,Y28andH27inthearomaticregionofTOCSYspectra,localRMSDvaluesfortheseresidues,andpositivecross-peaksinaROESYspectrum(600MHz,100msmixingtime),suggestthattheseresiduesactasahingeallowingfortheoverallflexibilityoftheentireintegrin-bindingloop.Thesedistinctstructuralfeatures,alongwithitsdifferentelectrostaticsurfacepotentialinrelationtootherknowndisintegrins,mayconfertoobtustatinitsreportedalpha(1)beta(1)integrininhibitoryselectivity.
Moreno-MurcianoM.P., etal.(2003)NMRsolutionstructureofthenon-RGDdisintegrinobtustatin. J.Mol.Biol. PMID: 12742023
Smartox Biotechnolgy的多肽毒素产品如下:
1. 作用于钠离子通道(Sodium channel)的毒素
Toxin name | Catalog # | Target |
Phrixotoxin-3 | 13PHX003 | Selective blocker of Nav1.2 |
µ-conotoxin GIIIB | CON020 | Selective blocker of Nav1.4 |
µ-conotoxin CnIIIC | CON021 | Selective blocker of Nav1.4 |
μ-conotoxin PIIIA | 08CON006 | Selective blocker of Nav1.4 |
Jingzhaotoxin-III | 12JZH003 | Selective blocker of Nav1.5 |
ProTx-II | 07PTX002 | Selective blocker of Nav1.7 |
ProTx-II Biotin | 12PTB002 | Selective blocker of Nav1.7 |
ProTx-I | 12PTX001 | Blocker of Nav1.8, Nav1.2, Nav1.5, Nav1.7 |
Huwentoxin-I | 07HWT001 | Blocker of TTX-S |
Huwentoxin-IV | 08HWT002 | Blocker of TTX-S |
Hainantoxin-III | 13HTX003 | Blocker of TTX-S |
Hainantoxin-IV | 12HTX001 | Blocker of TTX-S |
GsAF-I | 12GSF001 | Blocker of TTX-S |
GsAF-II | 12GSF002 | Blocker of TTX-S |
2. 作用于钾离子通道(Potassium channel)的毒素
Toxin name | Catalog # | Target |
KCa channels | ||
Apamin 蜜蜂神经毒素 | 08APA001 | SK1, SK2, SK3 |
Charybdotoxin 蝎毒素 | 11CHA001 | KCa1.1, KCa3.1 - Kv1.2, Kv1.3, Kv1.6 |
Iberiotoxin | 12IBX001 | KCa1.1 |
Leiurotoxin 1 (Scyllatoxin) | 10LEI001 | SK1, SK2, SK3 |
Tamapin | 10TAM001 | SK1, SK2, SK3 |
Kaliotoxin-1 | 08KTX002 | BK, Kv1.1, Kv1.2, Kv1.3 |
Kv channels | ||
ShK | 08SHK001 | Kv1.3, Kv1.1, Kv1.4, Kv1.6 |
TMR-ShK | SAT001 | Kv1.3, Kv1.1 |
Margatoxin | 08MAG001 | Kv1.3 |
(Dap22)-ShK | 13SHD001 | Kv1.3 |
ADWX-1 | 13ADW001 | Kv1.3 |
HsTx1 | 08NEU001 | Kv1.3, Kv1.2 |
Agitoxin-2 | 13AGI002 | Kv1.3, Kv1.1 |
Maurotoxin | 08MAR001 | Kv1.2, KCa3.1 |
Guangxitoxin 1E | 11GUA002 | Kv2.1, Kv2.2 |
Stromatoxin 1 NEW | SCT01 | Kv2.1, Kv2.2 |
Kaliotoxin-1 | 08KTX002 | BK, Kv1.1, Kv1.2, Kv1.3 |
Charybdotoxin | 11CHA001 | KCa1.1, KCa3.1 - Kv1.2, Kv1.3, Kv1.6 |
Phrixotoxin-2 | PHX002 | Kv4.2, Kv4.3 |
AmmTx3 NEW | AMX001 | A-type potassium channels |
Inwardly rectifying potassium channels | ||
TertiapinQ | 08TER001 | Kir1.1, Kir3.1/3.4, Kir3.1/3.2-KCa1.1 |
hERG/Kv11.1 | ||
BeKm-1 | 13BEK001 | ERG1 |
3. 作用于钙离子通道(Calcium channel)的毒素
Toxin name | Catalog # | Target |
High voltage-gated Ca2+ channels | ||
ω-agatoxin IVA | 11AGA001 | P/Qtype |
ω-Conotoxin MVIIC | 08CON002 | P/Qtype, N-type |
ω-Conotoxin MVIIA | 08CON001 | N-type |
ω-Conotoxin GVIA | 08CON003 | N-type |
ω-Conotoxin SO3 | 08CON013 | N-type |
Huwentoxin I | 07HWT001 | N-type |
ProTx-II | 07PTX002 | T-type, L-type |
Intermediate voltage-gated Ca2+ channels | ||
SNX482 | 08SNX002 | R-type |
Low voltage-gated Ca2+ channels | ||
ProTx-I | 12PTX001 | T-type |
ProTx-II | 07PTX002 | T-type, L-type |
Ryanodine receptors | ||
Maurocalcine | 07PAU001 | Ryr1 |
4. 作用于氯离子通道(Chloride channel)的毒素
Toxin name | Catalog # | Target |
Chlorotoxin | 08CHL001 | Blocker of small conductance Cl- channels |
GaTx1 | 13GTX001 | Selective blocker of CFTR channel |
GaTx2 | 10GTX002 | Selective blocker of ClC-2 channel |
5. 作用于乙酰胆碱受体(Acetylcholine receptor)的毒素
Toxin name | Catalog # | Target |
α-conotoxin PeIA | 13CON017 | α9α10, α3β2 subunits |
α-Conotoxin PrXA | 13CON016 | α1/β1/ε/δ, α1/β1/γ/δ subunits |
Waglerin-1 | 12WAG001 | MusclenAChR |
α-conotoxin MI | 08CON012 | α1/δsubunits |
α-conotoxin GI | 08CON005 | α/δsite |
α-conotoxin IMI | 08CON011 | α7 homomeric nAChR |
α-conotoxin GID | CON019 | Blocker of α3β2, α7 and α4β2 nAChRs |
6. 含N-甲基-D-天冬氨酸NR2B
(NMDA, NR2B containing N-methyl-D-aspartate)
Conantokin-G
选择性、特异性抑制含NR2B的NMDAR。Conantokin-G能剂量依赖性抑制Ca2+内流,抑制NMDA诱导的兴奋性中毒效应。研究表明,在小鼠皮层神经元,Conantokin-G阻滞NMDA引发的电流信号的IC50值为480 nM。
7. 作用于酸敏感离子通道(ASIC channel, Acid-Sensing Ion Channel)的毒素
Toxin name | Catalog # | Target |
APETx2 | 07APE002 | Selective blocker of ASIC3 |
Psalmotoxin1/PcTx1 | 13PCT001 | Selective blocker of ASIC1a |
Ugr9-1 | 13UGR001 | Blocker of ASIC3 |
8. 作用于瞬时受体电位(TRP channel, transient receptor potential)的毒素
Toxin name | Catalog # | Target |
GsMTx4 | 08GSM001 | TRPC, TRPA |
Vanillotoxin3 | 10VAN003 | Activator of TRPV1 |
ProTx-I | 12PTX001 | Antagonist of TRPA1 |
9. 作用于嘌呤能通道(Purinergic channel)的毒素
Purotoxin-1
选择性抑制P2X3受体。100 nM Purotoxin-1 (PT-1)选择性抑制P2X3受体通道,在大鼠DRG神经元上,使用膜片钳实验表明:PT-1对电压门控通道和TRPV1均无抑制效应。10 µM ATP和100 µM α,β Methylene-ATP浓度下Purotoxin-1对P2X3受体有选择性作用,在该ATP浓度下Purotoxin-1对P2X2和杂化二聚体P2X2/3并无激动作用。Purotoxin-1对疼痛的潜在治疗作用。
10. 作用于其它膜受体通道(Others)的毒素
Smartox Biotechnology还提供其他类型的膜受体抑制剂:
Toxin name | Catalog # | Target |
Morphiceptin | 011CAS001 | Agonist of µ-opoid receptors |
Lys-conopressin G | 11CON14 | Vasopressin-like peptide |
GsMTx4 | 08GSM001 | Mechano sensitive ion channels |
Obtustatin | 10OBT001 | Blocks the binding of α1β1 integrin to collagen IV |
Rho-Conotoxin TIA | CON022 | Blocks α1-adrenergic receptor |
公司简介
Smartox Biotechnology是全球唯一一家专门生产动物毒液多肽毒素,用于细胞离子通道功能研究的生物医药公司。多肽毒素在生物制药领域具有重要的使用价值。
Smartox Biotechnology于2009年由来自Grenoble神经科学研究所(Grenoble Institute of Neuroscience)的Michel De Waard博士创立。Smartox Biotechnology专门研究动物毒液,制作合成多种毒液中的多肽成分(常称为毒素)。De Waard博士研究离子通道与毒素多肽的关系,尤其是鉴定、开发毒素多肽作为治疗性分子或细胞穿透肽(cell penetrating peptides, CPP)。其研究团队在毒液分离,药理性活性肽鉴定、富半胱氨酸肽定性、制作和优化等方面具有独特、丰富的经验。2010年,Smartox Biotechnolgy被法国研究部(Ministry of Research)授予“新兴企业OSEO奖(OSEO prize for emerging businesses)”。
总之,Smartox Biotechnolgy提供一系列高质量、具开创价值的多肽毒素。这些化合物在离子通道 研究中具有高的亲和性和选择性,是相应领域科学研究理想的生物毒素提供商和贴心的合作伙伴。